AstraZeneca : enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical

Submitted by Anonymous on

AstraZeneca : enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical Published on 07/14/2026 at 02:30 am EDT Publicnow Add MarketScreener to your sources Share ASTRAZENECA PLC -1.75%Complements AstraZeneca's leading portfolio of...

Papulopustular eruptions associated with EGFR-pathway-related targeted therapies: clinical spectrum, evidence boundaries, folliculocentric inflammation, and management considerations

Submitted by Anonymous on

Abstract Papulopustular eruption is a characteristic dermatologic toxicity of classical epidermal growth factor receptor (EGFR) inhibitors and may impair quality of life, supportive-care needs, and treatment continuity. Although frequently termed acneiform, it is distinct from acne vulgaris and is better...

Aptamer-based fluorescence “off-on” sensor for EGFR-positive lung cancer CTCs using streptavidin magnetic beads and N-CQDs@Ag⁺

Submitted by Anonymous on

Abstract Circulating tumor cells (CTCs) are rare but critical biomarkers for lung cancer diagnosis and metastasis monitoring. We report an aptamer-based fluorescence “off-on” sensor for the sensitive and specific detection of epidermal growth factor receptor (EGFR)-positive lung cancer CTCs. The...

Pratenol B, Eriodictyol, Losbanine, and Isookanin, as potential EGFR and HRAS inhibitors in oral squamous cell carcinoma

Submitted by Anonymous on

Oral squamous cell carcinoma (OSCC) is the most prevalent form of head and neck cancer and remains highly prevalent in developing countries. Disease management is challenged by the increasing prevalence of risk factors, limited treatment modalities, adverse side effects, and...

The Beclin1‑Targeting stapled peptide suppresses colorectal cancer progression by disrupting EGFR/β-catenin axis

Submitted by Anonymous on

AbstractBackground Colorectal cancer (CRC) remains a leading global cause of cancer-related mortality, demanding innovative therapies. Beclin1, a key autophagy and endolysosomal trafficking regulator with tumor-suppressive properties, is frequently downregulated in CRC. Although Beclin1 downregulation correlates with poor clinical outcomes, its...

Mesenchymal stem cell-induced metabolic reprogramming of EGFR-wild-type tumor cells drives therapeutic resistance in EGFR-mutant non-small cell lung cancer

Submitted by Anonymous on

AbstractBackground To explore mesenchymal stem cell (MSC)-driven metabolic reprogramming of EGFR-wild-type (EGFR-wt) tumor cells contributing to tyrosine kinase inhibitor (TKI) resistance in EGFR-mutant (EGFR-mt) non-small cell lung cancer. Methods Isolate MSCs from paired tumor and non-tumor lungs of EGFR-mt and...

Subscribe to Newsfeed